


## 2018 HIVR4P Satellite Session

### It only Hurts a Little: Long-Acting Injectable for Prevention and Treatment

#### Speaker Biographies



**Linda-Gail Bekker, MBChB, DTMH, DCH, FCP (SA), PhD**, is Professor of Medicine and Deputy Director of the Desmond Tutu HIV Centre at the Institute of Infectious Disease and Molecular Medicine, University of Cape Town. She is also Chief Operating Officer of the Desmond Tutu HIV Foundation. She is a physician scientist with a keen interest in HIV, tuberculosis and related diseases. Her research interests include programmatic and action research around antiretroviral roll out and TB integration, prevention of HIV in women, youth and men who have sex with men. She is immediate past President of the International AIDS Society and serves on a number of other national and international committees and boards.



**Le Minh Giang, MD, PhD**, is the Chair of the Department of Global Health and Head of the Office of Science and Technology at Hanoi Medical University in Vietnam. Dr. Giang also holds an adjunct faculty appointment in the Department of Sociomedical Sciences, Mailman School of Public Health of Columbia University where he is an alumnus. He has been PI and Co-PI of several NIH-funded studies on sexual health of MSM/TGW, substance use and HIV in Vietnam. He is also the PI of an ongoing MSM cohort study supported by PEPFAR/CDC in Hanoi, Vietnam that will start to offer oral PrEP for all of approximately 1500 participants from the beginning of 2019. With support from PEPFAR and SAMHSA, since 2012 he had led the development of Viet Nam-HIV Addiction Technology Transfer Center (V-HATTC) at Hanoi Medical University with the goal of developing addiction medicine workforce to confront substance use and HIV epidemics in Vietnam.



**Beatriz Grinsztejn, MD, PhD**, is an Infectious Diseases physician and researcher at the Evandro Chagas National Institute of Infectious Diseases/Oswaldo Cruz Foundation, in Rio de Janeiro, Brazil. She is the Director of the STD/AIDS Clinical Research Laboratory and Principal Investigator of the FIOCRUZ HIV Prevention and Therapeutic Clinical Trials Unit at FIOCRUZ, which is affiliated to the HIV Prevention Trials Network, the AIDS Clinical Trials Group and the ANRS. She implements Prevention and Therapeutic clinical trials and cohort studies. She is a member of the Brazilian Advisory Committee for Antiretroviral Therapy and HIV/AIDS Research, the WHO 2013 Adult Antiretroviral Therapy Guidelines Panel, the IAS-USA HIV Prevention Panel and the UNAIDS Scientific Expert Panel. Dr. Grinsztejn is a Faculty Member of the Masters and PhD Degree Program on Clinical Research in Infectious Diseases at Oswaldo Cruz Foundation.




**Raphael Landovitz, MD, MSc**, is Associate Professor of Medicine at the UCLA Center for Clinical AIDS Research & Education and Center Co-Director of CHIPTS. He has led combination prevention intervention studies and projects using Post-exposure (PEP) and Pre-exposure (PrEP) strategies for MSM, as well as being part of leadership groups of the DAIDS-funded AIDS Clinical Trials Group (ACTG), HIV Prevention Trials Network (HPTN) and the former Adolescent Trials Network (ATN). He is chair of the ACTG Antiretroviral Strategies Scientific Committee, the principal investigator of two multisite PrEP demonstration project in Los Angeles County, and leads the NIH/DAIDS-funded Phase 2 and Phase 3 registrational clinical trials evaluating long-acting injectable Cabotegravir for PrEP. His research agenda focuses on the optimization of the use of antiretroviral medications for both HIV treatment and HIV prevention.



**Jonathan Paul Lucas, MPH**, is a public health educationalist and leader with community engagement experience that spans two decades. He has a strong theoretical background in public health with practical experience in academic, community, and clinical settings. His primary focus includes implementation of various HIV/AIDS prevention and treatment programs and the support of community-based organizations (CBO) that implement cost-effective scalable programs and services to populations deemed vulnerable and hard to reach.



**Nyaradzo Mavis Mgodhi, MBChB, MMed**, is a clinical pathologist with over 10 years' experience conducting clinical trials assessing bio-medical HIV prevention methods for women of reproductive age in Zimbabwe and sub-Saharan Africa. She led HPTN-076, a phase II safety and acceptability study of injectable TMC278 LA for Pre-Exposure Prophylaxis (PrEP) in Harare. She is protocol co-chairperson for HVTN 703/HPTN 081 study, also known as Antibody Mediated Prevention (AMP) as well as for MTN-025/HOPE, an open label extension trial of the dapivirine vaginal ring for HIV prevention. In Zimbabwe, she is a lead investigator for HPTN-084, a phase III trial evaluating the relative safety and efficacy of oral and injectable cabotegravir in women. Nyaradzo is a member of the HIV Prevention Trials Network Executive Committee, as well as a scientific reviewer for the Medical Research Council of Zimbabwe. She served as a technical advisor for the Zimbabwe Population-based HIV Impact Assessment (ZIMPHIA) Survey. She is a member of the Policy and Implementation Steering Committee for the Global Evaluation of Microbicide Sensitivity (GEMS) project. GEMS is a project that aims to inform policies and define programmatic considerations related to use of ARV-based HIV- prevention products and risk of resistance.



**Santiago Moreno, PhD**, is the Chief of the Department of Infectious Diseases at the Hospital Ramón y Cajal, in Madrid, and is Professor of Infectious Diseases at the University of Alcalá de Henares, in Madrid. Dr. Moreno has been involved with HIV-infected patients since the very beginning of the AIDS epidemic in Spain. He has particular interest in antiretroviral therapy, HIV-related tuberculosis and other comorbidities, and HIV cure/eradication. He collaborates with the Spanish Ministry of Health in setting recommendations related to HIV infection/AIDS, including antiretroviral therapy, resistance testing, treatment, and prophylaxis of opportunistic infections. He is also the Founding President of VIHDA; an NGO developing a program of integral care for HIV infected patients in Maragua, Kenya. He has been the President of the Spanish Society for Infectious Diseases and Clinical Microbiology, and the Founding President of the Study Group for AIDS, in Spain.



**Aadia Rana, MD**, is an Associate Professor of Medicine at the University of Alabama-Birmingham (UAB) and an Associate Scientist with the UAB Center for AIDS Research. Dr. Rana's primary research area focuses on disparities in access and adherence to medical treatment among people living with HIV, and implementation of evidence-based interventions to improve engagement with HIV care. Her work incorporates health services research, behavioral sciences, social sciences, and clinical medicine. She has a career developmental grant from the National Institute of Mental Health evaluating postpartum retention in HIV care in Mississippi, and is co-chair of the AIDS Clinical Trials Group randomized control trial testing a strategy of long-acting injectable antiretroviral therapy with conditional economic incentives in HIV-infected patients with a history of non-adherence. She joined UAB from Brown University in 2017 where she is co-director of the UAB CFAR's Ending HIV in Alabama Scientific Working Group which includes a broad range of clinical, epidemiologic, socio-behavioral researchers as well as community and public health partners catalyzing Birmingham and Alabama's progression toward the UNAIDS 90-90-90 goals.



**Dianne Rausch, PhD** is the Director of the Division of AIDS Research at the National Institute of Mental Health (NIMH). She oversees the portfolio of extramural and network activities that study behavioral factors that intersect HIV/AIDS care and prevention. With the development of highly active ARVs, Dr. Rausch is interested in studying how behavioral and social factors, like mental health disorders, social determinants of health and stigma present barriers to optimal use of these medications in the settings of HIV prevention and treatment.



**Steven Shoptaw, PhD**, is a licensed psychologist and is the new Center Director for CHIPTS. He is Professor in the UCLA Departments of Family Medicine and Psychiatry and Bio-behavioral Sciences and Vice Chair of Research in Family Medicine. Dr. Shoptaw has a portfolio of work that focuses on the treatment of addiction and HIV prevention in the context of addiction in the Western U.S. where stimulant use is the single strongest predictor of HIV transmission. Dr. Shoptaw is a member of the DAIDS-funded, HIV Prevention Trials Network (HPTN) Executive Committee, and Clinical Site Leader for several HPTN studies, including HPTN 061, which documented that high-risk Black men who have sex with men (MSM) have 7% incidence in Los Angeles. Dr. Shoptaw also is MPI on a 5-year cooperative agreement (U01 DA036267; the MStudy) to establish a cohort of MSM of color to investigate interactions between non-injection use of methamphetamine, cocaine, opiates and binge drinking and HIV transmission dynamics.



**Omar Sued, MD, MSc, PhD**, is the Director of Clinical Research at Fundación Huésped. Dr. Sued is an internal medicine and infectious diseases specialist, with experience in the design and development of HIV clinical studies. He has particular interest in antiretroviral therapies, acute HIV infection, tuberculosis and immune HIV responses. From 2009 to 2012, Dr. Sued joined Pan American Health Organization's (PAHO), Regional World Health Organization Office for the Americas as the Regional Advisor for HIV treatment for Latin America and the Caribbean, where he supported LAC countries in the design of strategic plans and antiretroviral treatment national guidelines and coordinated a multi-country HHS-OGA grant focused on training in HIV for Central America. He is member of the Executive Committee of the Argentinean ID Society and President of the XVI National ID Congress.



**Mitchell Warren** has been the Executive Director of AVAC since 2004. He was previously the Senior Director for Vaccine Preparedness at the International AIDS Vaccine Initiative (IAVI), and also spent four years as Vice President and Director of International Affairs for The Female Health Company (FHC), the manufacturer of the female condom, where he directed efforts to design and implement reproductive health programs. Mitchell also spent six years at Population Services International (PSI) designing and implementing social marketing, communications and health promotion activities in Africa, Asia and Europe, including five years running PSI's project in South Africa. Mitchell is a member of the board of directors of the Global HIV Vaccine Enterprise; the WHO-UNAIDS HIV Vaccine Advisory Committee; the Office of AIDS Research Advisory Council of the US National Institutes of Health (NIH); and Maloto.